AMGN vs. GILD, MRNA, PFE, ABT, ISRG, SNY, ELV, SYK, NVS, and MDT
Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Pfizer (PFE), Abbott Laboratories (ABT), Intuitive Surgical (ISRG), Sanofi (SNY), Elevance Health (ELV), Stryker (SYK), Novartis (NVS), and Medtronic (MDT). These companies are all part of the "medical" sector.
Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, community ranking, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings.
Gilead Sciences received 923 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 77.37% of users gave Gilead Sciences an outperform vote while only 72.41% of users gave Amgen an outperform vote.
Amgen pays an annual dividend of $9.00 per share and has a dividend yield of 2.9%. Gilead Sciences pays an annual dividend of $3.08 per share and has a dividend yield of 4.5%. Amgen pays out 128.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 855.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.2% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Amgen has a net margin of 12.74% compared to Gilead Sciences' net margin of 1.76%. Amgen's return on equity of 156.21% beat Gilead Sciences' return on equity.
Amgen presently has a consensus target price of $305.65, suggesting a potential downside of 2.18%. Gilead Sciences has a consensus target price of $83.69, suggesting a potential upside of 23.58%. Given Gilead Sciences' higher probable upside, analysts plainly believe Gilead Sciences is more favorable than Amgen.
Amgen has higher revenue and earnings than Gilead Sciences. Amgen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.
Amgen has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.22, suggesting that its stock price is 78% less volatile than the S&P 500.
In the previous week, Amgen had 7 more articles in the media than Gilead Sciences. MarketBeat recorded 24 mentions for Amgen and 17 mentions for Gilead Sciences. Amgen's average media sentiment score of 0.64 beat Gilead Sciences' score of 0.45 indicating that Amgen is being referred to more favorably in the media.
Summary
Amgen beats Gilead Sciences on 14 of the 20 factors compared between the two stocks.
Get Amgen News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
